Insilico Medicine, a clinical-stage biotechnology company powered by generative artificial intelligence (AI), recently announced advancements to its unified AI framework for drug target discovery, integrating its previously introduced Target Identification Pro (
#TargetPro) and
#TargetIdentification Benchmark (TargetBench 1.0) into a validated system designed to improve the accuracy, reliability, and scalability of early-stage drug development.
Published in Scientific Reports, the framework demonstrates strong performance across benchmarking and real-world discovery workflows, reinforcing its role as a standardized foundation for AI-driven target identification.
#Drugdiscovery has long been constrained by high failure rates, with nearly 90% of clinical candidates failing—often due to weak or poorly validated biological targets. Insilico's integrated TargetPro–TargetBench framework addresses this challenge by combining disease-specific predictive modeling with rigorous, standardized evaluation.
Read the latest release here:
phys.org/news/2026-04-ai-dru…